Innoviva (INVA) Operating Leases (2019 - 2026)
Innoviva's (INVA) quarterly Operating Leases came in at $10.7 million in Q1 2026, up 879.29% YoY from $1.1 million in Q1 2025, and down 1.69% on a QoQ basis from $10.9 million in Q4 2025.
Analysis
Innoviva (INVA) Operating Leases (2019 - 2026) Analysis & Trends
Innoviva (INVA) has 6 years of Operating Leases data on file, last reported at $10.7 million in Q1 2026.
- Quarterly Operating Leases rose 879.29% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (up 879.29% YoY) and the FY2025 annual result came in at $10.9 million, up 821.8% from the prior year.
- Operating Leases eased to $10.7 million in Q1 2026, from $10.9 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $10.9 million in Q4 2025 to a low of $905000.0 in Q3 2025.
- A 5-year average of $2.9 million and a median of $2.0 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2025 — Operating Leases slumped 49.57% — and 2026, when it jumped 879.29%.
- Tracing INVA's Operating Leases over 5 years: stood at $2.4 million in 2022, then slumped by 31.19% to $1.6 million in 2023, then decreased by 27.89% to $1.2 million in 2024, then jumped by 821.8% to $10.9 million in 2025, then fell by 1.69% to $10.7 million in 2026.
- The last three Operating Leases figures came in at $10.7 million (Q1 2026), $10.9 million (Q4 2025), and $905000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.49 Mn |
| Mar 31, 2026 | 10.68 Mn |
| Dec 31, 2025 | 10.87 Mn |
| Sep 30, 2025 | 905,000.00 |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 1.95 Mn |
| Jun 30, 2023 | 1.86 Mn |
| Mar 31, 2023 | 2.10 Mn |
| Dec 31, 2022 | 2.38 Mn |
| Sep 30, 2022 | 2.70 Mn |
| Jun 30, 2022 | 3.09 Mn |
| Mar 31, 2022 | 3.30 Mn |
| Jun 30, 2019 | 1.16 Mn |
| Mar 31, 2019 | 1.24 Mn |